BACKGROUND: Extracorporeal photopheresis (ECP) is an important cell-based therapy for graft-versus-host disease (GVHD); however, the blood volume required per treatment to achieve a clinical response is unknown. STUDY DESIGN AND METHODS: We developed a mini-ECP technique (mini-ECP) using only 100 to 200 mL of whole blood for patients with contraindications for apheresis or low body weight. Sixteen patients (n=13 acute, n=3 chronic GVHD) with a median body weight of 19 kg (range, 7-48 kg) received 460 mini-ECP treatments with a median duration of 115 days (range, 49-973 days). RESULTS: Mini-ECP was well tolerated, and acute GVHD resolved completely in nine of 13 patients and partially in two patients but not in two patients. Cutaneous chronic GVHD exhibited a mixed response (one complete, one partial, and one no response). CONCLUSION: These results indicate mini-ECP as a novel and less invasive therapy for patients with GVHD and contraindications for apheresis.
BACKGROUND: Extracorporeal photopheresis (ECP) is an important cell-based therapy for graft-versus-host disease (GVHD); however, the blood volume required per treatment to achieve a clinical response is unknown. STUDY DESIGN AND METHODS: We developed a mini-ECP technique (mini-ECP) using only 100 to 200 mL of whole blood for patients with contraindications for apheresis or low body weight. Sixteen patients (n=13 acute, n=3 chronic GVHD) with a median body weight of 19 kg (range, 7-48 kg) received 460 mini-ECP treatments with a median duration of 115 days (range, 49-973 days). RESULTS: Mini-ECP was well tolerated, and acute GVHD resolved completely in nine of 13 patients and partially in two patients but not in two patients. Cutaneous chronic GVHD exhibited a mixed response (one complete, one partial, and one no response). CONCLUSION: These results indicate mini-ECP as a novel and less invasive therapy for patients with GVHD and contraindications for apheresis.
Authors: A Sauret; N Rabiau; E Rochette; V Grèze; P Halle; M Ouachée; J-H Dalle; E Seror; D Serraz; K Yakouben; D Adjaoud; A Pagnier; A Marie-Cardine-Bobbia; C Oudot; C Curtillet; M Poirée; J Kanold; E Merlin Journal: Bone Marrow Transplant Date: 2016-02-08 Impact factor: 5.483
Authors: C Pochon; L Reppel; P Halle; A Zang; L Clément; D Michel; A Perrot; G Roth-Guépin; M Detrait; J Kanold; N Rouel; B Donzé; V Décot; S Mathieu-Nafissi; E Merlin; D Bensoussan Journal: Bone Marrow Transplant Date: 2016-09-19 Impact factor: 5.483
Authors: Beatrice Drexler; Andreas Buser; Laura Infanti; Gregor Stehle; Joerg Halter; Andreas Holbro Journal: Transfus Med Hemother Date: 2020-05-19 Impact factor: 3.747
Authors: H Hackstein; A Kalina; T Jakob; G Bein; B Dorn; I S Keil; N Baal; G Michel; C Brendel; A Neubauer Journal: Clin Exp Immunol Date: 2020-11-08 Impact factor: 4.330